A $2.1 Billion Radiopharmaceutical Collaboration, Explained
This image was generated by AI and may not depict real events.
Regeneron Pharmaceuticals and Telix Pharmaceuticals have announced a $2.1 billion collaboration to develop and commercialize radiopharmaceutical therapies for cancer treatment. The partnership combines Regeneron's antibody expertise with Telix's specialized manufacturing capabilities, aiming to create next-generation cancer therapies.
Regeneron and Telix have formed a 50/50 collaboration to develop radiopharmaceuticals. The deal includes an upfront payment of $40 million for four initial programs, with options to expand and potential milestones of up to $535 million per program. Regeneron's antibody discovery platforms and clinical oncology portfolio will be combined with Telix's radiopharmaceutical development infrastructure and manufacturing capabilities. The partnership aims to create next-generation cancer therapies, including radio-diagnostic assets. Telix's infrastructure is designed to address the unique manufacturing and supply chain challenges of radiopharmaceuticals. The collaboration will focus on developing therapies for areas of high unmet patient need, such as lung cancer.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.